Verdict Machine
Who Is the Company Behind Verdict Machine?
- Seller: Verdict Machine
- HQ Location: N/A
-
LinkedIn® Page: linkedin.com
1 employees on LinkedIn®
Total Products under this Category: 1,333
Last updated: November 01, 2026
Why You Can Trust G2's Software Rankings:
G2's software rankings are built on verified user reviews, rigorous moderation, and a consistent research methodology maintained by a team of analysts and data experts. Each product is measured using the same transparent criteria, with no paid placement or vendor influence. While reviews reflect real user experiences, which can be subjective, they offer valuable insight into how software performs in the hands of professionals. Together, these inputs power the G2 Score, a standardized way to compare tools within every category.

Highlighted products: Gemini platform, SAS Viya, IBM watsonx.ai, Google Cloud Recommendations AI, Azure OpenAI Service, Amazon Personalize, Alteryx, and Google Cloud TPU.
Underlying data: [Grid® JSON](https://www.g2.com/categories/machine-learning/grids.json?focus%5B%5D=gemini-platform&focus%5B%5D=sas-sas-viya&focus%5B%5D=ibm-watsonx-ai&focus%5B%5D=google-cloud-recommendations-ai&focus%5B%5D=azure-openai-service&focus%5B%5D=amazon-personalize&focus%5B%5D=alteryx&focus%5B%5D=google-cloud-tpu)
VERDIS is an evolutionary supply chain decision-making platform enabled by Artificial Intelligence, Machine Learning & Big Data technologies, that helps enterprises move towards agile supply chains while catering to the uncertainties in supply, demand, and the ecosystem.
Average Rating: 4.0/5.0
Total Reviews: 1
"Verdis has been a life saver"
Rating: 4.0/5.0 stars
— Bhavit J.
Verge Genomics is a clinical-stage biotechnology company revolutionizing drug discovery by integrating artificial intelligence (AI) with human genomic data. Their proprietary CONVERGE® platform utilizes extensive multi-omic datasets derived directly from human tissues to identify and validate therapeutic targets, particularly for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Parkinson's disease. By focusing on human data from the outset, Verge aims to enhance the efficiency and success rates of developing novel treatments for complex conditions. Key Features and Functionality: - All-in-Human Data Platform: Verge has constructed one of the world's largest proprietary multi-omics databases sourced directly from human tissue, enabling a more accurate understanding of disease mechanisms. - CONVERGE® Machine Learning System: This AI-driven platform analyzes complex human genomic data to map disease pathways and identify potential drug targets with higher clinical translatability. - Integrated Target Validation: Combining computational predictions with experimental validation using patient-derived cells and advanced biological assays to establish causality and therapeutic potential. - Focus on Neurodegenerative Diseases: Dedicated to developing treatments for challenging conditions like ALS, Parkinson’s disease, and frontotemporal dementia with high unmet medical needs. - Collaborative Drug Development: Engages in strategic partnerships to advance promising targets into clinical trials, exemplified by a multi-year collaboration with Eli Lilly. Primary Value and Solutions: Verge Genomics addresses the critical challenge of high failure rates in traditional drug development by leveraging human-centric data and AI to improve the accuracy of target identification and validation. This approach reduces reliance on less predictive animal models, accelerates the drug discovery process, and increases the likelihood of clinical success. By focusing on diseases with significant unmet needs, Verge aims to deliver effective therapies more efficiently, ultimately improving patient outcomes in complex neurodegenerative conditions.
Connect G2 to Claude or ChatGPT for answers grounded in G2's trusted reviews, comparisons, and pricing from real user insights.
High definition fault detection technology for the next generation of smarter, longer lasting and more sustainable appliances
Vilisto is a Hamburg-based climate protection company specializing in digital heat management solutions for non-residential buildings. Their core product comprises intelligent thermostats equipped with patented, integrated sensors and self-learning algorithms that detect room usage patterns and automatically adjust temperatures accordingly. This technology enables organizations to reduce heating energy consumption by up to 32%, leading to significant cost savings and a substantial decrease in CO₂ emissions. Key Features and Functionality: - Intelligent Thermostats: Equipped with sensors and algorithms to detect room occupancy and optimize heating schedules without manual intervention. - Automated Heat Management: Adjusts heating based on actual room usage, ensuring energy is not wasted in unoccupied spaces. - Online Platform Integration: Provides real-time monitoring of energy consumption, savings, and room climate data, allowing for further optimization. - Adaptive Hydraulic Balancing: Enhances heating system efficiency by automatically balancing the distribution of heat within the building. Primary Value and Problem Solved: Vilisto addresses the challenge of energy waste in non-residential buildings, where rooms are often heated continuously regardless of occupancy. By implementing their digital heat management system, organizations can achieve substantial reductions in energy consumption and CO₂ emissions without compromising comfort. This solution not only leads to cost savings but also supports environmental sustainability goals.